Monoclonal Autoantibody Against a Cryptic Epitope on Tissue-Adherent Low-Density Lipoprotein for Molecular Imaging in Atherosclerosis.
暂无分享,去创建一个
R. Virmani | A. Finn | J. Boyle | H. Björkbacka | J. Nilsson | D. Haskard | Liang Guo | Shang-Hung Chang | A. Hartley | Mikhail Caga-Anan | C. Kojima | Ramzi Y Khamis | Samata S. Pandey | Cinzia Marceddu | Jason L. Johnson | R. Khamis | M. Caga-Anan
[1] F. Jaffer,et al. Intravascular Molecular-Structural Assessment of Arterial Inflammation in Preclinical Atherosclerosis Progression. , 2021, JACC. Cardiovascular imaging.
[2] Habib Samady,et al. Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study , 2019, The Lancet.
[3] Torsten Schwede,et al. SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..
[4] P. Matthews,et al. Near Infrared Fluorescence (NIRF) Molecular Imaging of Oxidized LDL with an Autoantibody in Experimental Atherosclerosis , 2016, Scientific Reports.
[5] R. Edwards,et al. Model IgG monoclonal autoantibody-anti-idiotype pair for dissecting the humoral immune response to oxidized low density lipoprotein. , 2012, Hybridoma.
[6] P. D. de Groot,et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. , 2010, Blood.
[7] M. Sternberg,et al. Protein structure prediction on the Web: a case study using the Phyre server , 2009, Nature Protocols.
[8] S. Gordon,et al. Macrophage scavenger receptors and host-derived ligands. , 2007, Methods.
[9] P. D. de Groot,et al. Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. , 2006, Blood.
[10] G. Pasterkamp,et al. Athero-express: Differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design , 2004, European Journal of Epidemiology.
[11] P. Shah,et al. Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[12] G. Berglund,et al. Identification of Immune Responses Against Aldehyde-Modified Peptide Sequences in ApoB Associated With Cardiovascular Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[13] J. Borén,et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis , 2002, Nature.
[14] J. Segrest,et al. Structure of apolipoprotein B-100 in low density lipoproteins. , 2001, Journal of lipid research.
[15] M. Carrier,et al. Distribution of Lipid Deposits Around Aortic Branches of Mice Lacking LDL Receptors and Apolipoprotein E , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[16] John M. Hancock,et al. The structure of vitellogenin provides a molecular model for the assembly and secretion of atherogenic lipoproteins. , 1999, Journal of molecular biology.
[17] M. Ferguson,et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. , 1998, Circulation.
[18] S. Bhakdi,et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety , 1995, The Journal of experimental medicine.
[19] G. Bondjers,et al. Modifications of low-density lipoprotein induced by arterial proteoglycans and chondroitin-6-sulfate. , 1991, Biochimica et biophysica acta.
[20] A. Gotto,et al. Isolation and characterization of sulfhydryl and disulfide peptides of human apolipoprotein B-100. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[21] L. Romics,et al. Binding of fibronectin to human lipoproteins. , 1989, Clinica chimica acta; international journal of clinical chemistry.
[22] J. Archer,et al. Cross-reactivity between solid-phase immunoassay plates and intermediate filaments demonstrated by human monoclonal antibodies. , 1985, Journal of immunological methods.
[23] G. Camejo,et al. The structural stability of low-density lipoprotein. A kinetic X-ray scattering study of its interaction with arterial proteoglycans. , 1984, Biochimica et biophysica acta.
[24] M. Bihari-varga,et al. Changes in the physical behavior of low density lipoprotein in the presence of glycosaminoglycans and high density lipoprotein. , 1981, Atherosclerosis.